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Abstract
 
Vascular damage induced by trauma, inflammation, or infection results in an alteration of the
endothelium from a nonactivated to a procoagulant, vasoconstrictive, and proinflammatory
state, and can lead to life-threatening complications. Here we report that activation of the con-
tact system by 
 
Salmonella 
 
leads to massive infiltration of red blood cells and fibrin deposition in
the lungs of infected rats. These pulmonary lesions were prevented when the infected animals
were treated with H-D-Pro-Phe-Arg-chloromethylketone, an inhibitor of coagulation factor
XII and plasma kallikrein, suggesting that inhibition of contact system activation could be used
therapeutically in severe infectious disease.
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Introduction
 
Hemostasis is a sensitive and tightly regulated process, in-
volving vascular endothelium and blood cells as well as fac-
tors of the coagulation and fibrinolytic cascades. During in-
fection, inflammatory mediators of the microbe and/or
host may induce life-threatening complications by modu-
lating the equilibrium between the procoagulant and anti-
coagulant status of the host (1). The activation of the in-
trinsic pathway of coagulation, also termed contact system,
during infection is thought to contribute to the severity of
the disease (for a review, see reference 2). The contact sys-
tem belongs to the typical serine proteinase–triggered cas-
cades, which are initiated by limited proteolysis (3). Upon
activation, the system is involved in the regulation of dif-
ferent proinflammatory and defense mechanisms (4). In se-
vere infections, low levels of contact factors (factor [F] XII
and H-kininogen [HK])
 
1
 
 correlate with a fatal outcome of
the disease (5). Most strains of 
 
Salmonella typhimurium 
 
bac-
teria can express so-called thin, aggregative fimbriae (for
simplicity, referred to as fimbriae in the following text) on
their surface, whereas very similar structures in 
 
Escherichia
coli
 
 are designated curli (6–8). These fibrous proteins inter-
act with several host proteins such as contact system factors,
fibrinogen, fibronectin, laminin, major histocompatibility
complex class I antigens, and plasminogen (9–12). Re-
cently, it was shown that curli organelles from 
 
E. coli
 
 trig-
ger the induction of cytokines IL-1
 
a
 
, IL-1
 
b
 
, IL-6, IL-8,
and TNF-
 
a
 
 in peripheral blood monocytes, suggesting a
possible role for these organelles in the initiation of proin-
flammatory reactions during 
 
E. coli
 
 sepsis (13). The assem-
bly of contact system factors on the surface of fimbriae-
expressing bacteria leads to the release of the inflammatory
mediator bradykinin. Furthermore, the binding of contact
factors and fibrinogen to fimbriae results in the depletion of
these proteins in plasma and causes a hypocoagulatory state
(9). These mechanisms should contribute to symptoms of
severe 
 
Salmonella
 
 and 
 
E. coli
 
 infections, i.e., plasma leakage
into the extravascular space, hypovolemic hypotension, and
formation of microthrombi.
Extraintestinal salmonellosis is most common among im-
munosuppressed, debilitated patients with underlying dis-
eases such as AIDS, leukemia, lymphoma, inflammatory
bowel disease, schistosomiasis, and macrophage dysfunction
(14). The most frequent isolates from patients with extrain-
 
testinal salmonellosis are the fimbriae-expressing strains 
 
S.
typhimurium
 
 and 
 
Salmonella enteritidis 
 
(7, 8, 15–17). In this
investigation, we show that inhibition of the contact system
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downregulates inflammatory reactions and coagulation dis-
orders induced by fimbriae-expressing 
 
S. typhimurium
 
.
 
Materials and Methods
 
Bacterial Strains and Culture Conditions.
 
The 
 
S. typhimurium
 
SR-11 X4666 strain (SR11B) was used. The CsgA and CsgB
mutant strains (SR-11 X4666, csgA::Tn1731; SR-11 X4666,
csgB::Tn1721) were produced by transposon mutagenesis (18).
Bacteria were grown on colonization factor antigen agar (19) at
37
 
8
 
C overnight, washed, and resuspended in 0.15 M NaCl, 0.03 M
NaH
 
2
 
PO
 
4
 
, pH 7.2, containing: 0.02% (wt/vol) NaN
 
3
 
 and 0.05%
(vol/vol) Tween (buffer A); 13 mM sodium citrate, pH 7.4
(buffer B); 15 mM Hepes, 135 mM NaCl, 50 
 
m
 
M ZnCl
 
2
 
, pH 7.4
(buffer C); or 0.15 M NaCl, 4 mM KCl, and 2 mM CaCl
 
2
 
, pH
6.0 (buffer D).
 
Sources of Proteins.
 
Coagulation factors F VII, F IX, F X, F
XI, F XII, prothrombin, and von Willebrand factor, were from
Haematologic Technologies Inc. F V, HK, and plasma kallikrein
(PK) were from Enzymes Research Laboratories Ltd., and fibrin-
ogen was from Sigma-Aldrich. Proteins were iodinated by the
chloramin-T method of Fraker and Speck (20). The H-D-Pro-
Phe-Arg-chloromethylketone (CMK) peptide was from Bachem
Feinchemikalien AG.
 
Plasma.
 
Blood samples were drawn from healthy volunteers
in Vacutainer tubes (Becton Dickinson) containing 1:9 vol, 129
mM sodium citrate, pH 7.4, or in tubes (Terumo) containing so-
dium heparin (1,500 USP units sodium heparin/10 ml). Drawn
blood was pooled and centrifuged at 2,500 
 
g
 
 for 15 min. The pel-
let was removed and plasma samples were stored at 
 
2
 
20
 
8
 
C.
 
Binding Assays.
 
Bacteria resuspended in buffer A were ad-
justed to a final count of 2 
 
3
 
 10
 
9
 
 cells/ml. Binding assays were
performed as described previously (9). In brief, 200 
 
m
 
l of cell sus-
pensions was incubated with 25 
 
m
 
l (8 
 
3
 
 10
 
5
 
 cpm/ml) radioac-
tively labeled protein for 1 h at room temperature. Samples were
washed with 1 ml buffer A, followed by a centrifugation step
(1,500 
 
g
 
, 15 min). The supernatant was removed and the radioac-
tivity in the pellet was counted. Binding was expressed as the per-
centage of bound versus total radioactivity.
 
Clotting Assays.
 
The clotting time was measured in a coagu-
lometer (Amelung). 30 
 
m
 
l of bacteria suspended in buffer B
(0.1
 
 
 
–2 
 
3
 
 10
 
10
 
 cells/ml) was incubated with 100 
 
m
 
l human cit-
rate–treated plasma for 1 min (activated partial thromboplastin
time [aPTT]) or 2 min (prothrombin [PT]) at 37
 
8
 
C. Clotting was
initiated by the addition of 100 
 
m
 
l Platelin LS (aPTT kit; Orga-
non Teknica) for 200 s at 37
 
8
 
C followed by the addition of 100
 
m
 
l 25 mM CaCl
 
2
 
 (aPTT) or 200 
 
m
 
l Tromboplastin-XS with cal-
cium (PT; Sigma-Aldrich). Alternatively, 0.5 ml citrate-treated
plasma was preincubated with 0.5 ml of a solution containing
10
 
10
 
 bacteria/ml in the presence or absence of 50 
 
m
 
g/ml H-D-
Pro-Phe-Arg-CMK (final concentration). After incubation for 15
min at room temperature, bacteria were removed by centrifuga-
tion (2,500 
 
g
 
, 10 min), and the resulting supernatants were ana-
lyzed as described above.
 
Chromogenic Substrate Assay.
 
SR11B bacteria were washed
and adjusted to 2 
 
3
 
 10
 
10
 
 bacteria/ml in buffer C. Equal volumes
(0.5 ml) of bacteria and citrate-treated plasma were incubated for
15 min at room temperature in the presence or absence of 50 
 
m
 
g/
ml H-D-Pro-Phe-Arg-CMK (final concentration). The samples
were then washed three times in buffer C and resuspended in
0.25 ml of a buffer containing 1 mM of the chromogenic sub-
strate S-2302 (H-D-Pro-Phe-Arg-pNA
 
?
 
2HCl specific for F XII
and PK) or S-2238 (H-D-Phe-Pip-Arg-pNA
 
?
 
2HCl specific for
thrombin). Both substrates were from Chromogenix. After incu-
bation for 30 min at room temperature, the bacteria were centri-
fuged at 8,000 
 
g
 
 for 2 min and the absorbance of the supernatants
at 405 nm was measured.
 
Determination of Bradykinin.
 
Bacteria were washed and ad-
justed to 2 
 
3
 
 10
 
10
 
 cells/ml in buffer C. Equal volumes (0.5 ml) of
bacteria and fresh heparin-treated plasma were incubated for 15
min at room temperature in the presence or absence of 100 
 
m
 
g/
ml H-D-Pro-Phe-Arg-CMK (final concentration). The samples
were then centrifuged at 10,000 rpm for 1 min and resuspended
in the same buffer, followed by three washing steps, and finally
resuspended in 0.25 ml. After 15 min of incubation at room tem-
perature, the bacteria were removed by centrifugation (10,000
rpm, 1 min) and the bradykinin concentration in the reaction
mixture was quantified by the Markit-A kit (Dainippon Pharma-
ceutical Co.) as described (21).
 
Animal Experiments.
 
Adult Wistar rats, weighing 250–275 g,
were anesthetized with equal parts of fluanison/fentanyl (10/0.2
mg/ml Hypnorm; Janssen Pharmaceutica) and midazolam (5 mg/
ml Dormicum; Hoffman-La Roche) diluted 1:1 with sterile wa-
ter (0.2 ml/100 g body wt intramuscularly). The trachea was can-
nulated to facilitate spontaneous breathing. Catheters were placed
in the left jugular vein for intravenous administration of bacterial
suspensions, and in the right carotid artery for systemic blood
pressure recordings. Rats were given an intravenous injection of
250 
 
m
 
l of a bacterial suspension containing 2 
 
3
 
 10
 
10
 
 cells/ml in
buffer D. Alternatively, 100 
 
m
 
l of a solution containing 4 mg/ml
H-D-Pro-Phe-Arg-CMK in buffer D was intravenously injected
into rats and after 10 min, 350 
 
m
 
l of a mixture containing 400 
 
m
 
g
peptide and 5 
 
3
 
 10
 
9
 
 bacteria was administrated via the same
route. 30 min after injection of bacteria, blood samples were
taken by puncture of the heart. Thereafter, rats were killed by an
overdose of anesthesia and the lungs were removed. The animal
experiments were approved by the regional ethical committee for
animal experimentation.
 
Histochemistry.
 
After killing, lungs were rapidly removed by
surgery and fixed at 4
 
8
 
C for 24 h in buffered 4% formalin (pH
7.4; Kebo). Tissues were dehydrated and imbedded in paraffin
(Histolab Products AB), cut into 4-
 
m
 
m sections, and mounted.
After removal of the paraffin, tissues were stained with Mayers
hematoxylin (Histolab Products AB) and eosin (Surgipath Medi-
cal Industries, Inc.).
 
Scanning Electron Microscopy.
 
Clots or lung tissue were fixed
in 2% (vol/vol) glutaraldehyde, 0.1 M sodium cacodylate, and
0.1 M sucrose, pH 7.2, for 2 h at 4
 
8
 
C, and subsequently washed
with 0.15 M cacodylate, pH 7.2. Clots and tissue samples were
postfixed with 1% (wt/vol) osmium tetroxide and 0.15 M so-
dium cacodylate, pH 7.2, for 1 h at 4
 
8
 
C, washed, and stored in
cacodylate buffer. Before scanning electron microscopy, samples
were dehydrated with an ascending ethanol series from 50 to
100% ethanol (10 min per step). They were then subjected to
critical-point drying in liquid carbon dioxide with 100% ethanol
as the intermediate solvent, mounted on aluminum holders, sput-
tered with 50 nm palladium/gold, and examined in a Jeol JSM-
350 scanning electron microscope.
 
Statistics.
 
Results are expressed as mean values 
 
6
 
 SD unless
otherwise stated. Differences between groups concerning brady-
kinin release, hemorrhagic lung lesions, and fibrin deposition
were analyzed by the one-tailed test for differences between
means. The following a priori null hypotheses were tested: H-D-
Pro-Phe-Arg-CMK treatment does not alter bradykinin release
from human plasma, or does not prevent hemorrhagic lesions and 
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fibrin deposition in rat lungs induced by 
 
Salmonella
 
. The null hy-
pothesis was rejected and statistical significance was assumed
when
 
 P 
 
,
 
 0.05.
 
Results
 
Coagulation Factors Bind to Fimbriated Salmonella.
 
To ex-
plore a potential role for fimbriated bacteria in coagulation
disorders and inflammation, we assessed the binding of var-
ious radiolabeled coagulation factors to 
 
S. typhimurium
 
,
strain SR11B. The isogenic mutant strains CsgA and CsgB
that do not express fimbriae were used as controls. Fig. 1
shows that all tested factors had affinity for SR11B bacteria,
whereas, with the exception of fibrinogen binding to CsgA
bacteria, the mutant strains did not bind the various pro-
teins. The interactions between SR11B bacteria and coag-
ulation factors were not dependent on phospholipids; how-
ever, the binding was slightly increased when a buffer
containing ZnCl
 
2
 
 (50 
 
m
 
M) was used (data not shown). Af-
ter incubation of SR11B bacteria with plasma and careful
washing, all coagulation factors could also be eluted from
the bacterial surface and detected by Western blot analysis.
In addition, after plasma incubation and washing, serine
proteinase activity associated with the bacterial cell surface
was increased as measured by specific chromogenic sub-
strates (data not shown).
Figure 1. The binding of radiolabeled coagula-
tion factors to fimbriated Salmonella.  125I-labeled
HK, PK, F XII, F XI, F X, F IX, F VII, F V, pro-
thrombin, fibrinogen, or von Willebrand factor was
incubated with suspensions of S. typhimurium strains
SR11B, CsgA, or CsgB. Binding is expressed as the
percentage of bound vs. total radioactivity. Data
represent means 6 SD of three experiments, each
done in duplicate.
Figure 2. Effects of Salmonella on the clotting time.
Normal human plasma was incubated with increasing
concentrations of strains SR11B (j), CsgA (r), CsgB
(d), or buffer alone (control) for 60 s. Clotting was initi-
ated by adding kaolin and CaCl2 (A), or tissue factor (B).
Data represent means 6 SD of three experiments, each
done in duplicate. 
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Fimbriated Bacteria Interfere with the Activation of the Intrinsic
but Not the Extrinsic Pathway of Coagulation.
 
Based on the
findings described above, it was investigated whether the
interaction between SR11B bacteria and coagulation fac-
tors influenced the clotting properties of normal human
plasma. Therefore, we tested the effect of SR11B on clot
formation by measuring the aPTT and the PT. Fig. 2 A
shows that the addition of SR11B bacteria to plasma pro-
longed clotting by the intrinsic pathway (aPTT) in a con-
centration-dependent manner, whereas the extrinsic path-
way (PT) was not effected (Fig. 2 B). The ability of SR11B
bacteria to attenuate the intrinsic pathway is due to absorp-
tion of contact factors and other coagulation factors such as
F XII by fimbriae leading to a hypocoagulatory state, as de-
scribed previously (9). The mutant strains CsgA and CsgB
did not influence the clotting ability of plasma, neither of
the intrinsic nor extrinsic pathway. The results demonstrate
 
that the binding of coagulation factors to SR11B is medi-
ated by fimbriae, resulting in impaired clot formation via
the intrinsic pathway of coagulation.
 
The Release of Bradykinin by Salmonella Is Blocked by an In-
hibitor of F XII and PK.
 
The synthetic peptide H-D-Pro-
Phe-Arg-CMK is an inhibitor of F XII and PK (22, 23),
and when added to human plasma it caused an up to 14-
fold prolongation of the aPTT, but had almost no influence
on the PT (Fig. 3). The results emphasize its specificity for
F XII/PK and the intrinsic pathway of coagulation.
It was then tested whether the peptide could interfere
with the bradykinin release induced by fimbriated 
 
Salmo-
nella. Fig. 4 shows that such bacteria generate large amounts
of bradykinin when added to human plasma, a release that
was completely blocked in the presence of H-D-Pro-Phe-
Arg-CMK. Also, the effect of kaolin, a potent activator of
the contact system, was blocked by the F XII/PK inhibitor.
The mutant strains had no or only minor influence on
bradykinin generation, and incubations with plasma alone
or plasma plus the inhibitor served as additional controls
(Fig. 4). In summary, the data demonstrate that fimbriated
Salmonella in plasma activates the proinflammatory pathway
of the contact system, i.e., kinin generation, and that this
activation can be blocked by a specific inhibitor of F XII
and PK.
Electron Microscopical and Functional Analysis of Clots
Formed in the Absence or Presence of H-D-Pro-Phe-Arg-CMK.
To further investigate the ability of H-D-Pro-Phe-Arg-
CMK to interfere with the activation of the contact sys-
tem by fimbriated bacteria, we studied the influence of the
inhibitor on clot formation by scanning electron micros-
copy. As this method allows for analyzing surface topogra-
phy in a three-dimensional way at high resolution, it ap-
peared to be a suitable tool to visualize alterations in fibrin
fibril architecture in clots formed in the presence or ab-
sence of bacteria. Clots induced in plasma by kaolin are
built by long, polymerized fibrin fibrils forming an intact
network (Fig. 5 A). The addition of H-D-Pro-Phe-Arg-
CMK to plasma did not influence this general architecture,
but the clotting time was drastically prolonged (Fig. 5 B).
Upon incubation of plasma with SR11B bacteria, the clot
Figure 3. The effects of H-D-Pro-Phe-Arg-CMK on the clotting
time. Normal human plasma was incubated with increasing concentra-
tions of the synthetic peptide H-D-Pro-Phe-Arg-CMK (1–100 mg/ml fi-
nal concentration) for 60 s. Clotting was initiated by adding kaolin and
CaCl2 (j), or tissue factor (r), and the clotting times are given as time-
fold prolongation.
Figure 4. The ex vivo effects of H-D-Pro-Phe-Arg-
CMK on the generation of bradykinin by kaolin and Sal-
monella. Human plasma samples, in the absence or presence
of H-D-Pro-Phe-Arg-CMK (100 mg/ml final concentra-
tion), were incubated with kaolin or with strains SR11B,
CsgA, or CsgB for 15 min. Plasma was removed by cen-
trifugation and kaolin or bacteria were resuspended as de-
scribed in Materials and Methods. After 15 min of incuba-
tion, the amount of bradykinin present in the reaction
mixture was measured by a competitive ELISA. As a con-
trol, plasma was incubated in the absence of kaolin and
bacteria. Data represent means 6 SD of three experiments.
P values between SR11B and CsgA or CsgB are indicated
in the figure.1419 Persson et al.
morphology changed. Bacteria were incorporated into the
clot, the length and diameter of the fibrin fibrils were
shortened, and an intact network was not established (Fig.
5 C). These findings are in line with previously reported
data and are due to the absorption and activation of coagu-
lation factors on the bacterial surface, resulting in an im-
paired clotting ability and hypocoagulative state (9). In
contrast, the fibrin fibrils and network formation appeared
to be normal when SR11B bacteria were added to plasma
treated with H-D-Pro-Phe-Arg-CMK, although some
bacteria were found adhering to the fibers (Fig. 5 D). The
mutant strains CsgA (Fig. 5, E and F) and CsgB (not
shown) had no influence on the clot morphology.
To investigate if the contact activation at the surface of
SR11B influences other surface-bound coagulation fac-
tors, chromogenic substrates specific for F XII/PK or
thrombin amidolytic activity were used. When SR11B
bacteria were incubated with human plasma in the absence
of H-D-Pro-Phe-Arg-CMK, enhanced activity for F XII/
PK was associated with bacterial surface compared with
the control (Fig. 6 A). Similar results were obtained when
the activity of thrombin was investigated (Fig. 6 B). How-
ever, no hydrolysis of the substrates for F XII/PK and
thrombin was found when plasma was treated with H-D-
Pro-Phe-Arg-CMK (Fig. 6, A and B). Thus, the differ-
ences in the morphology of clots obtained from plasma in-
cubated with SR11B bacteria in the absence or presence of
H-D-Pro-Phe-Arg-CMK can be explained by the contact
system–triggered activation of the coagulation cascade on
the bacterial surface leading to an activation of thrombin,
Figure 5. Scanning electron
micrographs of clots from human
plasma formed in the presence or
absence of H-D-Pro-Phe-Arg-
CMK. Representative electron
micrographs show clots formed
in human plasma incubated with
strains SR11B (C and D) and
CsgA (E and F), in the absence
(A, C, and E) or presence (B, D,
and F) of H-D-Pro-Phe-Arg-
CMK. Plasma samples without
bacteria served as controls (A and
B). Scale bar, 5 mm.1420 Salmonella, Lung Lesions, and the Contact System
probably followed by a degradation of bacterially bound
fibrinogen.
The effect of H-D-Pro-Phe-Arg-CMK was also re-
flected in the clotting ability of plasma samples that had
been treated with fimbriated bacteria. In these experi-
ments, the assay was modified such that plasma in the ab-
sence or presence of H-D-Pro-Phe-Arg-CMK was in-
cubated with bacteria for 15 min, followed by a
centrifugation step to remove the bacteria. This manipula-
tion results in more extended clotting times compared
with the experiments described above because the longer
incubation time (15 min compared with 1 min) allows
plasma proteins to adhere to the bacterial surface. The
binding and subsequent depletion of various coagulation
factors additionally disturb normal clotting of plasma (9).
Bacteria were removed and the resulting supernatants
were analyzed in the aPTT and PT tests. Incubation of
plasma with buffer alone served as the control, and a con-
centration of the inhibitor was chosen (50 mg/ml) that in-
duced an increase of z120 s of the aPTT compared with
untreated plasma (Fig. 7 A). The absorption of plasma
with SR11B bacteria led to a prolongation of the aPTT of
z30 s. However, when H-D-Pro-Phe-Arg-CMK was
first added to plasma followed by absorption, clot forma-
tion was completely blocked. In the absence of H-D-Pro-
Phe-Arg-CMK, the PT clotting time of plasma samples
preabsorbed with SR11B bacteria was not prolonged for
.5 s compared with untreated plasma (Fig. 7 B). More-
over, in the PT test the addition of the inhibitor to plasma
followed by treatment with SR11B did not block fibrin
clotting, though the clotting time was prolonged (32.6 6
2.0 vs. 22.6 6 2.2 s in plasma incubated with H-D-Pro-
Phe-Arg-CMK). Plasma samples preabsorbed by CsgA or
CsgB bacteria were not affected in either the aPTT or the
PT test. Taken together, electron microscopical analysis
and clotting assays suggest that the disturbances of normal
clotting induced by fimbriated bacteria are overcome by
H-D-Pro-Phe-Arg-CMK, as formation of bacteria con-
taining fibrin deposits due to contact activation on the
Figure 6. The activation of
coagulation factors bound to
SR11B bacteria in the absence
or presence of H-D-Pro-Phe-
Arg-CMK. SR11B bacteria
were preincubated with plasma
in the absence or presence of
H-D-Pro-Phe-Arg-CMK (50
mg/ml final concentration) for
15 min at room temperature. As
a control, bacteria were incu-
bated with buffer alone. Bacteria
were washed as described in
Materials and Methods and re-
suspended in a buffer containing
the chromogenic substrate H-D-
Pro-Phe-Arg-pNA?2HCl spe-
cific for F XII/PK (A) or H-D-
Phe-Pip-Arg-pNA?2HCl spe-
cific for thrombin (B). After 30
min, bacteria were removed and
the absorbance at 405 nm was
determined.
Figure 7. The effects of H-D-Pro-Phe-Arg-CMK on the clotting of
plasma preabsorbed with bacteria. Human plasma samples, in the absence
or presence of H-D-Pro-Phe-Arg-CMK (50 mg/ml final concentration),
were incubated with strains SR11B, CsgA, or CsgB for 15 min. Bacteria
were separated from plasma by centrifugation and the resulting superna-
tants were analyzed by the aPTT (A) or the PT (B) test. Data represent
means 6 SD of three experiments, each done in duplicate.1421 Persson et al.
bacterial surface is abolished. The data also show that fim-
briated bacteria fail to block the extrinsic pathway of coag-
ulation and that this pathway remains functional in plasma,
in the presence of H-D-Pro-Phe-Arg-CMK.
H-D-Pro-Phe-Arg-CMK Prevents Lung Damage in Rats In-
fected with Fimbriated Salmonella Bacteria. In a series of ex-
periments, a single bolus of SR11B bacteria was injected
intravenously into anesthetized rats. Half of the animals
were treated with H-D-Pro-Phe-Arg-CMK, and rats in-
jected with vehicle alone served as controls. After injec-
tions, the blood pressure was monitored in two animals of
each group. Within 30 min after infection, the blood pres-
sure dropped 55 mmHg in both rats infected with SR11B,
whereas the decline was 25 and 35 mmHg, respectively, in
the two infected rats treated with the inhibitor. No signifi-
cant differences of bradykinin levels were found in blood
plasma samples from infected and control animals (data not
shown). This is explained by the fact that kinins are rapidly
metabolized by different peptidases such as kininase I, kini-
nase II (also known as angiotensin 1–converting enzyme),
and neutral endopeptidase, resulting in a half-life of brady-
kinin of z10 s in rats (24).
The extent of lung damage was analyzed by histochemi-
cal staining and light microscopy of tissue sections from in-
fected and noninfected animals. Fig. 8 A depicts the intact
alveolar architecture of an untreated control animal. Infec-
tion with SR11B gave rise to widespread hemorrhages and
massive erythrocyte infiltration of lung parenchyma and
bronchioles (Fig. 8 B); lesions were much less prominent in
infected animals treated with H-D-Pro-Phe-Arg-CMK
(Fig. 8 C). Thus, the ratio between damaged and undam-
aged tissue areas, quantified and summarized in Table I,
shows significantly less damage in the lungs of rats treated
with H-D-Pro-Phe-Arg-CMK compared with nontreated
animals.
Lung tissue sections were analyzed by scanning electron
microscopy, and representative samples from uninfected
rats are shown in Fig. 9, A and B. Micrographs of lungs
from infected rats reveal that, in addition to the findings
described above, the alveolar system exhibits extensive fi-
brin deposition (Fig. 9 C). Furthermore, bacteria are seen
either incorporated in the fibrin network or adhering to
erythrocytes (Fig. 9 D). These lesions were not found in
the lungs of rats treated with H-D-Pro-Phe-Arg-CMK
Figure 8. The histological analysis of rat lungs. Formalin-fixed sections
of rat lungs were stained with hematoxylin and eosin. The figure shows
representative sections of lungs from an uninfected rat (A), a rat infected
with SR11B bacteria (B), and a rat infected with SR11B bacteria and
treated with H-D-Pro-Phe-Arg-CMK (C). Pulmonary arteries (A) and
bronchioles (B) are indicated. Scale bar, 25 mm.
Table I. Hemorrhagic Lesions in Rat Lungs
Animal Buffer SR11B
SR11B 1
H-D-Pro-Phe-Arg-CMK
%% %
1 3.5 41.6 6.6
2 4.0 16.5 11.7
3 8.1 26.9 11.8
4 6.8 60.7 14.0
Eight rats were infected with SR11B bacteria, from which four were
treated with H-D-Pro-Phe-Arg-CMK. Noninfected animals injected
with buffer alone served as controls and four animals in each group were
analyzed. The ratio of hemorrhagic area versus total area was determined
by light microscopy in six randomly chosen lung tissue sections from
each animal. Hemorrhagic lesions in control animals, considered as
background, occur upon removal and preparation of lung tissue. The P
value for the difference between lesions induced by SR11B in the
absence or presence of H-D-Pro-Phe-Arg-CMK is ,0.001.1422 Salmonella, Lung Lesions, and the Contact System
(Fig. 9, E and F). Alveolar swelling was clearly less pro-
nounced, but still also present in the treated rats. Table II
shows that administration of H-D-Pro-Phe-Arg-CMK sig-
nificantly reduces fibrin deposition and bacterial tissue in-
vasion in all animals tested. Thus, the in vivo data suggest
that activation of the contact system by fimbriated bacteria
induces extravascular leakage, bleeding, and fibrin deposi-
tion in the lung. The results also demonstrate that these ef-
fects can be prevented by an F XII/PK inhibitor.
Discussion
The lung is a common site for primary and secondary in-
fections (25). Pleuropulmonary complications also contrib-
ute significantly to the morbidity and mortality of serious
and generalized infections such as sepsis. Lung infections
caused by Salmonella are rare, except in immunocompro-
mised individuals (26). However, the experimental ap-
proach used here makes it possible to investigate the effect
of contact system activation by bacteria in lung tissue. In-
travenous injection targets the bacteria to the lungs, and
Figure 9. Scanning electron
microscopy of rat lungs. The fig-
ure shows micrographs of glu-
taraldehyde-fixed lungs from an
uninfected rat (A and B), a rat
infected with SR11B bacteria (C
and D), and a rat infected with
SR11B bacteria and treated with
H-D-Pro-Phe-Arg-CMK (E
and F). Arrows point to erythro-
cytes and arrowheads to bacteria
adhering to erythrocytes. Bars,
10 mm (A, C, and E) and 100
mm (B, D, and F).
Table II. Quantification of Fibrin Deposition in Rat Lungs
Animal Control SR11B
SR11B 1
H-D-Pro-Phe-Arg-CMK
%% %
1 2.3 87.7 18.2
2 3.1 60.1 19.1
3 3.4 71.8 19.9
4 2.1 87.1 23.1
Eight rats were infected with SR11B bacteria, from which four were
treated with buffer or H-D-Pro-Phe-Arg-CMK. Noninfected animals
injected with buffer alone served as controls and four animals in each
group were analyzed. The ratio of the area containing fibrin deposition
versus total area was determined by electron microscopy in six randomly
chosen lung tissue sections from each animal. Fibrin deposition in vessels
was not subtracted. The P value for the difference in fibrin deposition
induced by SR11B in the absence or presence of H-D-Pro-Phe-Arg-
CMK is ,0.001.1423 Persson et al.
previous work has demonstrated that fimbriated Salmonella
efficiently activates the contact system (9). Finally, the ac-
cess to well-defined isogenic Salmonella mutants devoid of
contact system–activating fimbriae facilitated the design of
distinct control experiments.
Bradykinin is a primary mediator of inflammation, in-
ducing pain, vasodilatation, and increased vascular perme-
ability (27). Previous work has shown that the contact sys-
tem is assembled and activated not only at the surface of
fimbriated Salmonella. Strains of E. coli and Streptococcus pyo-
genes expressing fibrous surface proteins also have this ca-
pacity (9, 11, 28, 29). Moreover, our ongoing work shows
that  Staphylococcus aureus, yet another important human
pathogen, efficiently activates the contact system, empha-
sizing that this mechanism represents a common and im-
portant virulence determinant. It is likely that contact sys-
tem activation adds selective advantages to the bacteria. A
local release of bradykinin will cause leakage of plasma into
the infectious focus and provide growing bacteria with nu-
trients. An increased vascular permeability should also facil-
itate the dissemination of the infection. Moreover, a hypo-
coagulative state in the infectious focus will also avoid
entrapment of bacteria in a fibrin network.
In relation to this investigation, a massive release of
bradykinin in the lungs leading to a damaged vascular bar-
rier is fully compatible with the lesion observed in rats in-
jected with fimbriated Salmonella. This assumption is fur-
ther substantiated by the finding that the administration of
a specific inhibitor of the contact system blocked pulmo-
nary plasma leakage and blood cell infiltration. In addition,
the pronounced effect of H-D-Pro-Phe-Arg-CMK sug-
gests that synthetic inhibitors based on this structure could
be used to treat serious complications in infectious diseases.
Such small synthetic molecules have major advantages.
First, they do not interfere with the extrinsic tissue factor–
driven coagulation pathway, and should therefore not
aggravate bleeding disorders often associated with severe
infections. Second, when bound to negatively charged sur-
faces, PK in complex with HK and F XII are protected
from their physiological inhibitor, C1 inhibitor (30–32).
Our initial experiments also indicate that C1 inhibitor fails
to block the activation of PK and F XII bound to bacterial
surfaces. Similar findings were obtained by studying the in-
teraction between plasmin and different bacterial species,
showing that the plasmin absorbed by S. pyogenes and Borre-
lia burgdorferi is protected from inhibition by a2-plasmin in-
hibitor (33, 34). The administration of peptide derivatives
specifically interfering with activated F XII and PK, there-
fore, represents a novel and potentially interesting approach
in the treatment of severe complications of infections
caused by bacteria capable of activating the contact system.
At a time when microbial resistance to antibiotics is be-
coming a rapidly increasing medical problem, therapeutic
strategies focused primarily on significant pathophysiologi-
cal mechanisms have clear advantages compared with anti-
biotic therapy. Such treatment is also often initiated too
late and without clinical effect in cases of acute and severe
infectious diseases.
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